| 前收市價 | 47.51 |
| 開市 | 47.52 |
| 買盤 | 46.83 x 200 |
| 賣出價 | 50.93 x 200 |
| 今日波幅 | 46.69 - 48.19 |
| 52 週波幅 | 19.83 - 94.75 |
| 成交量 | |
| 平均成交量 | 1,361,108 |
| 市值 | 5.663B |
| Beta 值 (5 年，每月) | 0.89 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -4.45 |
| 業績公佈日 | 2024年5月02日 - 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 82.13 |
ZacksApellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Insider Monkey30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
Insider MonkeyApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript February 27, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.73 EPS, expectations were $-0.66. Apellis Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning […]
